Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours

被引:56
作者
Bartkova, J
Falck, J
Rajpert-De Meyts, E
Skakkebæk, NE
Lukas, J
Bartek, J
机构
[1] Inst Canc Biol, Danish Canc Soc, DK-2100 Copenhagen O, Denmark
[2] Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark
关键词
cell cycle checkpoints; Chk2; spermatogenesis; carcinoma in situ; testicular germ-cell tumours;
D O I
10.1038/sj.onc.1204746
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chk2 is a transducer of DNA damage signals and a tumour suppressor whose germ-line mutations predispose to diverse tumour types. Unlike its downstream targets such as the p53 tumour suppressor, the expression patterns of Chk2 in tissues and tumours remain unknown. As DNA breaks occur commonly during gametogenesis, and p53 is wild-type and overexpressed in testicular cancer, we examined abundance and localisation of the Chk2 protein during normal development of human testes, and at various stages of germ-cell tumour (GCT) pathogenesis. Our results show that Chk2 is abundant in foetal germ cells and adult spermatogonia, yet only weakly expressed or lacking during the meiotic and later stages of spermatogenesis. High levels of Chk2 are detected in the majority of GCTs including all preinvasive carcinoma-in-situ lesions, contrary to variable expression and even lack of Chk2 in subsets of invasive GCTs and some teratoma structures, respectively. Together with our analyses of cell culture models, these results indicate that downmodulation or lack of Chk2 is not simply attributable to quiescence or differentiation, they suggest a role for Chk2 in mitotic rather than meiotic divisions, support the concept of foetal origin of GCTs, and have implications for protein-based screening for tumour-associated aberrations of Chk2.
引用
收藏
页码:5897 / 5902
页数:6
相关论文
共 31 条
  • [2] Partial rescue of the prophase I defects of Atm-deficient mice by p53 and p21 null alleles
    Barlow, C
    Liyanage, M
    Moens, PB
    Deng, CX
    Ried, T
    WynshawBoris, A
    [J]. NATURE GENETICS, 1997, 17 (04) : 462 - 466
  • [3] Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis
    Bartkova, J
    Thullberg, M
    Rajpert-De Meyts, E
    Skakkebæk, NE
    Bartek, J
    [J]. ONCOGENE, 2000, 19 (36) : 4146 - 4150
  • [4] P53 PROTEIN ALTERATIONS IN HUMAN TESTICULAR CANCER INCLUDING PREINVASIVE INTRATUBULAR GERM-CELL NEOPLASIA
    BARTKOVA, J
    BARTEK, J
    LUKAS, J
    VOJTESEK, B
    STASKOVA, Z
    REJTHAR, A
    KOVARIK, J
    MIDGLEY, CA
    LANE, DP
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (02) : 196 - 202
  • [5] Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO
  • [6] 2-A
  • [7] Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
    Bell, DW
    Varley, JM
    Szydlo, TE
    Kang, DH
    Wahrer, DCR
    Shannon, KE
    Lubratovich, M
    Verselis, SJ
    Isselbacher, KJ
    Fraumeni, JF
    Birch, JM
    Li, FP
    Garber, JE
    Haber, DA
    [J]. SCIENCE, 1999, 286 (5449) : 2528 - 2531
  • [8] Chaganti RSK, 2000, CANCER RES, V60, P1475
  • [9] Chehab NH, 2000, GENE DEV, V14, P278
  • [10] Cressman VL, 1999, MOL CELL BIOL, V19, P7061